Weigel J W, Mebust W K, Foret J D, Noble M J, Votapka T, Krishnan E C, Jewell W R
Urology. 1985 Feb;25(2):103-5. doi: 10.1016/0090-4295(85)90522-9.
The authors have used xenogeneic immune ribonucleic acid (RNA) in the treatment of patients with renal cell carcinoma. This has been used in conjunction with renal artery embolization, delayed nephrectomy, and progestational therapy, using immune RNA derived from sheep cell lymphocytes immunized with patient's tumor. Four of 5 patients with Stage I disease had extremely large primary tumors. This group is alive with no evidence of disease at twelve to twenty-four months. There are no Stage II tumors in this group. One patient with Stage III tumor is alive at twenty-two months without evidence of disease. Three patients with metastases are stable at five to twenty-two months. Two patients have progressive disease at three and six months. This treatment has not been effective in patients with massive tumor burden. The results in the other groups are encouraging.
作者们使用异种免疫核糖核酸（RNA）治疗肾细胞癌患者。它与肾动脉栓塞、延迟性肾切除术及孕激素疗法联合使用，所使用的免疫RNA源自用患者肿瘤免疫的绵羊细胞淋巴细胞。5例I期疾病患者中有4例有极大的原发性肿瘤。该组患者在12至24个月时存活且无疾病证据。该组中没有II期肿瘤患者。1例III期肿瘤患者在22个月时存活且无疾病证据。3例有转移的患者在5至22个月时病情稳定。2例患者在3个月和6个月时病情进展。这种治疗方法对肿瘤负荷大的患者无效。其他组的结果令人鼓舞。
